- Home
- MNMD vs UAN Comparison
MNMD vs UAN Comparison
Compare MNMD & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- UAN
- Stock Information
- Founded
- MNMD 2019
- UAN 2007
- Country
- MNMD United States
- UAN United States
- Employees
- MNMD N/A
- UAN N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- UAN Agricultural Chemicals
- Sector
- MNMD Health Care
- UAN Industrials
- Exchange
- MNMD Nasdaq
- UAN Nasdaq
- Market Cap
- MNMD 811.9M
- UAN 930.2M
- IPO Year
- MNMD N/A
- UAN 2011
- Fundamental
- Price
- MNMD $12.51
- UAN $93.51
- Analyst Decision
- MNMD Strong Buy
- UAN
- Analyst Count
- MNMD 6
- UAN 0
- Target Price
- MNMD $26.50
- UAN N/A
- AVG Volume (30 Days)
- MNMD 1.8M
- UAN 19.8K
- Earning Date
- MNMD 11-06-2025
- UAN 10-27-2025
- Dividend Yield
- MNMD N/A
- UAN 7.27%
- EPS Growth
- MNMD N/A
- UAN 77.68
- EPS
- MNMD N/A
- UAN 8.32
- Revenue
- MNMD N/A
- UAN $576,184,000.00
- Revenue This Year
- MNMD N/A
- UAN N/A
- Revenue Next Year
- MNMD N/A
- UAN N/A
- P/E Ratio
- MNMD N/A
- UAN $11.33
- Revenue Growth
- MNMD N/A
- UAN 8.15
- 52 Week Low
- MNMD $4.70
- UAN $62.94
- 52 Week High
- MNMD $12.94
- UAN $98.99
- Technical
- Relative Strength Index (RSI)
- MNMD 66.16
- UAN 58.70
- Support Level
- MNMD $11.81
- UAN $92.20
- Resistance Level
- MNMD $12.94
- UAN $94.99
- Average True Range (ATR)
- MNMD 0.86
- UAN 1.58
- MACD
- MNMD 0.17
- UAN 0.31
- Stochastic Oscillator
- MNMD 88.48
- UAN 65.85
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.